In a subgroup of 3184 breast cancer survivors diagnosed after 2010, when HER2 status was available, 68.4% of their prior breast cancers were luminal A molecular subtype (ER-positive and/or PR-positive and HER2-negative). This evidence concerns the gene ERBB2 and breast cancer.